China Conditionally Approves Fanregratinib in FGFR2 Cholangiocarcinoma

Company: HUTCHMED · Drug: Fanregratinib (ATLED) · Indication: FGFR2 Fusion/Rearrangement Intrahepatic Cholangiocarcinoma · Regulatory Action: NMPA Conditional Approval · Date: August 28, 2026 Summary China’s National Medical Products Administration granted conditional approval to HUTCHMED’s fanregratinib, marketed as ATLED, for adults with advanced, metastatic or unresectable…